# Tissue Regenix: Profitable Growth and Strategic Expansion

- Link: https://www.directorstalkinterviews.com/tissue-regenix-profitable-growth-and-strategic-expansion/4121171528
- Published: 2024-09-23T09:03:14+01:00
- Author: Amilia Stone

**Tissue Regenix Group plc **(LON:TRX) is focused on the development and commercialisation
of two proprietary processing technologies for the repair of soft tissue (dCELL®)
and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics
and dental markets. Investment in tissue processing, manufacturing capacity and 
strong commercial partners, together with its “4S” strategy, has generated seven
consecutive reporting periods of strong growth, with TRX becoming profitable in 
1H’24. TRX is about to invest in Phase 2 of its capacity expansion programme, which
has the potential to take group sales up to $100m. TRX deserves to be re-rated, 
in our view.

 * **Strategy**: TRX is building a global regenerative medicine business around 
   its proprietary technology platforms, underpinned by compelling clinical outcomes.
   Phase 1 of its investment programme has grown sales to a point where TRX is cash-
   generative, which is being used to expand capacity further with Phase 2.
 * **Interims**: In 1H’24, Tissue Regenix reported double-digit (16.3%) sales growth
   for the seventh consecutive reporting period, generating sales of $16.4m ($14.1m).
   Growth was observed in all three divisions. EBITDA increased more than three-
   fold to $1.15m ($0.35m) and TRX generated its maiden PBT of $0.13m.
 * **Phase 2 capacity investment**: TRX has started Phase 2 of its capacity expansion
   programme to significantly increase the number of clean rooms, providing greater
   flexibility to satisfy changing demand and take group sales up to $100m. This
   programme is fully funded and expected to be completed by the end of 2025.
 * **Forecasts**: TRX has a diverse set of products, which are sold directly or 
   through strong partners. Unexpected headwinds affected the BioRinse range (+12%
   in 1H’24), but its processing flexibility was switched to dCELL (+34%). Higher
   gross margins in 1H’24 have been carried through to the full year, and 2025.
 * **Investment summary**: 2023 was a milestone year when Tissue Regenix was fully
   EDITDA-positive and cash-generative in 2H’23. Further growth in 1H’24 has seen
   the group become EBIT- and PBT-profitable. Cash generation is being used to expand
   processing and manufacturing further through Phase 2 of its capacity investment
   programme in 2025. This is a quality operation with very strong partners. An 
   EV/sales multiple of 4x 2025E sales generates a valuation of $159m/£120m.

[240923-Hardman-Tissue-Regenix-TRX-Maiden-pre-tax-profit](https://www.directorstalkinterviews.com/wp-content/uploads/2024/09/240923-Hardman-Tissue-Regenix-TRX-Maiden-pre-tax-profit.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2024/09/240923-Hardman-Tissue-Regenix-TRX-Maiden-pre-tax-profit.pdf)

Share on:
